Peripheral blood mononuclear cells in vitro — Personalization model of antipsychotic therapy. Tsitologiya, 60(7):549-554, 2018. cited By 0![Peripheral blood mononuclear cells in vitro — Personalization model of antipsychotic therapy [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Unified antipsychotic therapy strategy has proven ineffective approach to mental patient treatment. Pharmacological drug effectiveness study on model organisms reflecting the individual pathophysiology of the patients is one of the directions of personified/predictive therapy. During research we estimated mRNA levels of neurotransmitter receptor genes (ADR1B, HRH1, HTR2A, DRD1, DRD2, DRD4 and DRD5) which are affected by antipsychotics as possible biomarkers of the forecasting of schizophrenic range disorder therapy during in vitro modulating therapy (haloperidol or olanzapine) on peripheral blood mononuclear cells (PBMC). The study included 108 patients with schizophrenic range disorders. Based on psychometric study results under therapy by antipsychotics (28 2 days) the patients were divided into pharmacotherapy response groups (effective/low-efficiency). The mRNA expression levels of the studied genes in cultivated in vitro PBMC in the presence of antipsychotic significantly increased in the group of patients with low-efficiency therapy, whereas in the group of patients with a good dynamic of mental status recovery they remained almost unchanged. The highest reliability of differences in the gene expression level for patients with different responses to pharmacological effects was achieved for ADR1B and HRH1 under olanzapine therapy (P = 0.004 and P = 0.038, respectively) and for HTR2A under haloperidol therapy (P = 0.039). At the same time, baseline mRNA expression levels of genes in PBMCs (without culturing) were not associated with the patient response to therapy. Thus, mRNA expression levels of neurotransmitter genes in in vitro cultured PBMCs in the presence of antipsychotic can be offered as a biomarker of the forecasting of mental patient pharmacotherapy. © 2018 Sankt Peterburg.All rights reserved.
Downloads: 0
{"_id":"oYCFeJsZssKPXzcjb","bibbaseid":"anonymous-peripheralbloodmononuclearcellsinvitropersonalizationmodelofantipsychotictherapy-2018","bibdata":{"bibtype":"article","type":"article","author":[{"propositions":[],"lastnames":["Grunina"],"firstnames":["M.N."],"suffixes":[]},{"propositions":[],"lastnames":["Zabotina"],"firstnames":["À.Ì."],"suffixes":[]},{"propositions":[],"lastnames":["Pchelina"],"firstnames":["M.M."],"suffixes":[]},{"propositions":[],"lastnames":["Nasyrova"],"firstnames":["R.F."],"suffixes":[]},{"propositions":[],"lastnames":["Sosin"],"firstnames":["D.N."],"suffixes":[]},{"propositions":[],"lastnames":["Ershov"],"firstnames":["Å.Å."],"suffixes":[]},{"propositions":[],"lastnames":["Taraskina"],"firstnames":["À.Å."],"suffixes":[]},{"propositions":[],"lastnames":["Krupitsky"],"firstnames":["Å.Ì."],"suffixes":[]}],"title":"Peripheral blood mononuclear cells in vitro — Personalization model of antipsychotic therapy","journal":"Tsitologiya","year":"2018","volume":"60","number":"7","pages":"549-554","doi":"10.31116/tsitol.2018.07.12","note":"cited By 0","url":"https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064700426&doi=10.31116%2ftsitol.2018.07.12&partnerID=40&md5=235eebfe3d4226970d1c91835221b510","affiliation":"B. P. Konstantinov Petersburg Nuclear Physics Institute, National Research Centre Kurchatov Institute, Gatchina, Leningrad Region, 188300, Russian Federation; I. P. Pavlov First St. Petersburg State Medical University, Ministry of Healthcare of Russian Federation, St. Petersburg, 197022, Russian Federation; V. M. Bekhterev National Medical Research Centre Psychiatry and Neurology, St. Petersburg, 192019, Russian Federation; P. P. Kashchenko St. Petersburg Psychiatric Hospital No. 1, Leningrad Region, Gatchina District, Village Nikolskoe, 188357, Russian Federation","abstract":"Unified antipsychotic therapy strategy has proven ineffective approach to mental patient treatment. Pharmacological drug effectiveness study on model organisms reflecting the individual pathophysiology of the patients is one of the directions of personified/predictive therapy. During research we estimated mRNA levels of neurotransmitter receptor genes (ADR1B, HRH1, HTR2A, DRD1, DRD2, DRD4 and DRD5) which are affected by antipsychotics as possible biomarkers of the forecasting of schizophrenic range disorder therapy during in vitro modulating therapy (haloperidol or olanzapine) on peripheral blood mononuclear cells (PBMC). The study included 108 patients with schizophrenic range disorders. Based on psychometric study results under therapy by antipsychotics (28 2 days) the patients were divided into pharmacotherapy response groups (effective/low-efficiency). The mRNA expression levels of the studied genes in cultivated in vitro PBMC in the presence of antipsychotic significantly increased in the group of patients with low-efficiency therapy, whereas in the group of patients with a good dynamic of mental status recovery they remained almost unchanged. The highest reliability of differences in the gene expression level for patients with different responses to pharmacological effects was achieved for ADR1B and HRH1 under olanzapine therapy (P = 0.004 and P = 0.038, respectively) and for HTR2A under haloperidol therapy (P = 0.039). At the same time, baseline mRNA expression levels of genes in PBMCs (without culturing) were not associated with the patient response to therapy. Thus, mRNA expression levels of neurotransmitter genes in in vitro cultured PBMCs in the presence of antipsychotic can be offered as a biomarker of the forecasting of mental patient pharmacotherapy. © 2018 Sankt Peterburg.All rights reserved.","author_keywords":"Antipsychotic drugs; mRNA level; Peripheral blood mononuclear cells; Predictors of therapy efficacy; Receptors of neurotransmission; Schizophrenia spectrum disorders","funding_details":"National Research Centre188300","key":"Grunina2018549","id":"Grunina2018549","bibbaseid":"anonymous-peripheralbloodmononuclearcellsinvitropersonalizationmodelofantipsychotictherapy-2018","role":"author","urls":{"Paper":"https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064700426&doi=10.31116%2ftsitol.2018.07.12&partnerID=40&md5=235eebfe3d4226970d1c91835221b510"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bio.pnpi.nrcki.ru/wp-content/uploads/2019/12/lmgch_2019_10.txt","dataSources":["87fXC3NAxFNMB5YTH"],"keywords":[],"search_terms":["peripheral","blood","mononuclear","cells","vitro","personalization","model","antipsychotic","therapy"],"title":"Peripheral blood mononuclear cells in vitro — Personalization model of antipsychotic therapy","year":2018}